Reported 2 days ago
Jefferies analyst Tycho Peterson reaffirmed a Buy rating on Exact Sciences Corporation (NASDAQ:EXAS) on August 21, with a price target set at $80.00. The company reported a record revenue of $811 million for Q2 2025, a 16% increase, and raised its revenue guidance. Exact Sciences specializes in cancer detection and offers tests like Cologuard for colorectal cancer screening. Despite its investment potential, some analysts suggest AI stocks may offer better returns.
Source: YAHOO